Replies to post #216854 on Innovation Pharmaceuticals Inc (IPIX)

[TheDane]

Let’s break it down to bullet points:

These recent data, taken in aggregate...

1) satisfied actively engaged pharmaceutical companies’ request (for this data)

2) triggered a newfound flurry of inbound partnership discussions

3) reflect three successfully completed Phase 2 studies across which multiple endpoints were met

4) brought the Company to an important inflection point regarding Brilacidin

In coming weeks:

1) advancing these discussions with attractive partnership/licensing scenarios

2) determining the best path forward for the Company and its loyal shareholders.

[BooDog]

Very good point. The chatter I've seen on boards suggests the same. That we don't need full data to partner brilacidin.

The Company is now working to complete the Clinical Study Report (CSR). The CSR is central for engaging with the FDA to further discuss program development, and is also an important component for informing already advanced OM partnership discussions.

I think we'll soon be in the same boat with prurisol. Getting topline data soon imo.



https://clinicaltrials.gov/archive/NCT02949388/2016_10_30

Message in reply to:

BooDog We are not waiting on full data for a Brilacidin deal.
The CDA people have what they requested. This is from Leo's 1/16/2018 PR.
IMO Any day or week now:)

What must be stressed is that Brilacidin is a mature, later-stage drug candidate with platform potential. It took the recent completion of two Phase 2 trials, in IBD and OM, to further validate the exceptional results achieved from our Phase 2b study in ABSSSI. These recent data, taken in aggregate, are what various actively engaged pharmaceutical companies have desired from us for some time—and they are what triggered a newfound flurry of inbound partnership discussions at the San Francisco conferences,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Datasets now in hand, reflecting three successfully completed Phase 2 studies across which multiple endpoints were met, have brought the Company to an important inflection point regarding Brilacidin. In coming weeks, we look forward to advancing these discussions with attractive partnership/licensing scenarios, towards determining the best path forward for the Company and its loyal shareholders.”

[rmzport]

runninggirl...Brilacidin, this says it all!! Cuts through all the bull crap regardless how thick a layer the bullshitters that reside here try to spread. Please, just repost this every time the crims show up.

"What must be stressed is that Brilacidin is a mature, later-stage drug candidate with platform potential. It took the recent completion of two Phase 2 trials, in IBD and OM, to further validate the exceptional results achieved from our Phase 2b study in ABSSSI. These recent data, taken in aggregate, are what various actively engaged pharmaceutical companies have desired from us for some time—and they are what triggered a newfound flurry of inbound partnership discussions at the San Francisco conferences,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Datasets now in hand, reflecting three successfully completed Phase 2 studies across which multiple endpoints were met, have brought the Company to an important inflection point regarding Brilacidin. In coming weeks, we look forward to advancing these discussions with attractive partnership/licensing scenarios, towards determining the best path forward for the Company and its loyal shareholders.”
"